17 completed, 1 active not recruiting, 1 terminated, 1 unknown. 20 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 20 | Completed 17, Active not recruiting 1, Terminated 1, Unknown 1 |
| Phase 2 | 4 | Completed 2, Active not recruiting 1, Unknown 1 |
Follow Mesalamine: new trials by email Literature Review of Mesalamine trials Research Report on Mesalamine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Administration of Hydroxychloroquine (Plaquenil) to African Americans and Hispanics for the Treatment of Mild to Severe Ulcerative Colitis Hydroxychloroquine, Mesalamine - Ulcerative Colitis (Disorder) | Phase 1 / Phase 2 | Active not recruiting | Icahn School of Medicine at Mount Sinai | 3 | 2022-06-10 | 2025-02-11 |
| Randomized,Study of APRISO 375 mg Versus the Approved APRISO 375 mg Capsules in Healthy Male and Female Subjects Apriso 0.375G ER CAP, APRISO 375 mg extended-release capsules - Ulcerative Colitis | Phase 1 | Completed | Bausch Health Americas, Inc. | 60 | 2017-05-15 | 2018-05-08 |
| Role of Intestinal Protozoa and Helminths in the Course of Ulcerative Colitis parasitological diagnostics (coproscopy), Nitazoxanide 500Mg Oral Tablet, Mesalazine 250Mg Tablet and nitazoxanide 500Mg Oral Tablet - Ulcerative Colitis, Ulcerative Colitis Exacerbation | Phase 1 / Phase 2 | Unknown | Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan | 300 | 2015-01-01 | 2023-03-03 |
| Pharmacokinetics of IBD98-M 400mg-57.5/Day in Healthy Volunteers IBD98-M:, IBD98-M without HA, Delzicol - Healthy | Phase 1 | Completed | Holy Stone Healthcare Co., Ltd | 30 | 2014-07-01 | 2015-04-22 |
| Taste Assessment Study of SHP429 in Healthy Adult Subjects Mesalamine - Healthy | Phase 1 | Completed | Shire | 18 | 2014-06-02 | 2021-06-03 |
| TP0502-B-Pharmaco-Scintigraphic-Study TP05 - Ulcerative Colitis | Phase 1 | Completed | Tillotts Pharma AG | 9 | 2013-09-01 | 2014-12-04 |
| Mesalamine in Environmental Enteropathy Mesalamine, Placebo granules - Malnutrition | Phase 1 / Phase 2 | Completed | Kelsey Jones | 44 | 2013-06-01 | 2014-07-11 |
| TP0502-Pharmaco-Scintigraphic-Study and Amendment TP05 Coating D, TP05 Coating E, TP05 Coating H - Ulcerative Colitis | Phase 1 | Completed | Tillotts Pharma AG | 26 | 2012-10-01 | 2014-12-03 |
| TP0501 - Pharmaco-Scintigraphic-Study TP05 Coating A, TP05 Coating B - Ulcerative Colitis | Phase 1 | Completed | Tillotts Pharma AG | 18 | 2011-12-01 | 2014-12-03 |
| Sulfamethoxazole Drug Interaction Study With MMX® Mesalazine/Mesalamine sulfamethoxazole + MMX placebo, Sulfamethoxazole + MMX Mesalazine/mesalamine - Healthy | Phase 1 | Completed | Shire | 44 | 2011-11-07 | 2021-07-13 |
| Amoxicillin Drug Interaction Study With MMX® Mesalazine/Mesalamine Amoxicillin + MMX placebo, Amoxicillin + MMX mesalazine/mesalamine - Healthy | Phase 1 | Completed | Shire | 62 | 2011-10-07 | 2021-06-09 |
| Metronidazole Drug Interaction Study With MMX® Mesalazine/Mesalamine Metronidazole + MMX Mesalazine/mesalamine placebo, Metronidazole + MMX Mesalazine/mesalamine - Healthy | Phase 1 | Completed | Shire | 30 | 2011-08-22 | 2021-06-09 |
| Ciprofloxacin XR Drug Interaction Study With MMX® Mesalazine/Mesalamine Ciprofloxacin XR + MMX Placebo, MMX Mesalazine/mesalamine + Ciprofloxacin XR - Healthy | Phase 1 | Completed | Shire | 30 | 2011-07-25 | 2021-06-09 |
| Safety and Pharmacokinetics of MMX Mesalamine in Children and Adolescents With Ulcerative Colitis MMX Mesalamine - Ulcerative Colitis | Phase 1 | Completed | Shire | 52 | 2010-10-08 | 2021-06-14 |
| Targeting Oxidative Stress in Chronic Beryllium Disease Mesalamine, Placebo - Chronic Beryllium Disease | Phase 1 / Phase 2 | Completed | National Jewish Health | 18 | 2010-03-01 | 2018-10-12 |
| Study of the Safety and Tolerability of ALTH12 Versus Mesalamine Enema in Subjects With Left-Sided Ulcerative Colitis mesalamine, ALTH12-1:4, ALTH12-2:4 - Ulcerative Colitis | Phase 1 | Completed | Altheus Therapeutics, Inc. | 9 | 2009-11-01 | 2011-03-29 |
| PK Study of Encapsulated Mesalamine Granules in Healthy Volunteers mesalamine - Healthy | Phase 1 | Completed | Bausch Health Americas, Inc. | 24 | 2008-02-01 | 2019-11-18 |
| Pharmacokinetics of Asacol 2.4 g/Day and Lialda 2.4 g/Day in Healthy Volunteers Asacol, Lialda - Healthy | Phase 1 | Completed | Warner Chilcott | 37 | 2007-03-01 | 2013-04-17 |
| A Study of Asacol Absorption, Metabolism and Excretion in Children and Adolescents With Ulcerative Colitis. mesalamine - Ulcerative Colitis | Phase 1 | Terminated | Warner Chilcott | 34 | 2005-10-01 | 2013-04-17 |
| Effect of an Anti-Inflammatory Drug on Gut Mucosa in HIV Infected Patients 5-aminosalicylic acid - HIV Infections | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 14 | 1999-10-01 | 2007-05-25 |
Colitis, Ulcerative (9) · Inflammatory Bowel Diseases (2) · Berylliosis (1) · Colitis (1) · Diabetes Mellitus, Insulin-Dependent, 12 (1) · HIV Infections (1) · Inflammation (1) · Malnutrition (1) · Mucositis (1) · Protozoan Infections (1) · Trematode Infections (1)
Shire (6) · Tillotts Pharma AG (3) · Bausch Health Americas, Inc. (2) · Warner Chilcott (2) · Altheus Therapeutics, Inc. (1) · Holy Stone Healthcare Co., Ltd (1) · Icahn School of Medicine at Mount Sinai (1) · Kelsey Jones (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · National Jewish Health (1) · Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan (1)
United States (14) · Australia (1) · Canada (1) · Kenya (1) · Poland (1) · Slovakia (1) · United Kingdom (1)
Audrey Shaw, PhD (1) · Brian Day, PhD (1) · Denis Audet, M.D. (1) · Judy H Cho, MD (1) · Kelsey DJ Jones, MBBS BA MRCPCH (1) · Lisa A. Maier, M.D., MSPH (1) · Peter A. Anton, MD (1) · Philip B Miner, M.D. (1) · Subra Kugathasan, MD (1) · William Aronstein, MD, PhD (1) · William S Aronstein, MD, PhD (1)
PMID 24868146, PMID 25189855, PMID 26893546, PMID 32671846, PMID 33188747
K24AI001610 (1)